KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) EBT Margin (2016 - 2025)

Historic EBT Margin for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q3 2025 value amounting to 11903.49%.

  • CRISPR Therapeutics AG's EBT Margin rose 22270800.0% to 11903.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 1371.54%, marking a year-over-year decrease of 12399900.0%. This contributed to the annual value of 1082.43% for FY2024, which is 10336500.0% down from last year.
  • Per CRISPR Therapeutics AG's latest filing, its EBT Margin stood at 11903.49% for Q3 2025, which was up 22270800.0% from 23235.09% recorded in Q2 2025.
  • CRISPR Therapeutics AG's 5-year EBT Margin high stood at 84.75% for Q2 2021, and its period low was 2022866.67% during Q4 2022.
  • In the last 5 years, CRISPR Therapeutics AG's EBT Margin had a median value of 15548.64% in 2025 and averaged 138412.13%.
  • Per our database at Business Quant, CRISPR Therapeutics AG's EBT Margin crashed by 2000000000bps in 2022 and then surged by 2000000000bps in 2023.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's EBT Margin stood at 1112.5% in 2021, then plummeted by -181731bps to 2022866.67% in 2022, then skyrocketed by 100bps to 29.43% in 2023, then crashed by -841bps to 218.1% in 2024, then plummeted by -5358bps to 11903.49% in 2025.
  • Its EBT Margin stands at 11903.49% for Q3 2025, versus 23235.09% for Q2 2025 and 15593.87% for Q1 2025.